ハンミ医薬品は,BH3120,新型ガン予防療法で早期試験で保証されるBH3120の試験を推進する. Hanmi Pharmaceutical advances trials for BH3120, a new cancer immunotherapy showing promise in early tests.

ハンミ医薬品は北京ハンミ医薬品と併せて,BH3120(がん予防療法の革新的研究)BH3120の臨床試験を推進している. Hanmi Pharmaceutical, along with Beijing Hanmi Pharmaceutical, is advancing clinical trials for BH3120, an innovative cancer immunotherapy. 薬物目標 PD-L1 ガン細胞 4-1BB 免疫細胞 4-1B Bは 腫瘍と闘う 免疫系の能力を 高めることを目指す The drug targets PD-L1 on cancer cells and 4-1BB on immune cells, aiming to boost the immune system's ability to fight tumors. 初期試験では厳しい副作用は示さず,韓国では現在も現在も活動中であり,米国は高固形腫瘍の治療にMSDのCHTRUDAと併せてBH3120をテストしている. Early trials show no severe side effects and are ongoing in South Korea and the U.S. Hanmi is also testing BH3120 in combination with MSD's KEYTRUDA for treating advanced solid tumors.